Medcolcanna Organics Inc. has entered a Strategic Alliance Agreement with DNA Genetics. The terms of the agreement will allow Medcolcanna to benefit from DNA Genetics's experience in breeding, growing, and phenotyping activities, and to use DNA Genetics' proprietary high-quality strains, brands, and name for the commercialization of dried flower worldwide.
MCCN will also be producing under license DNA Genetics seeds to export to its own customers, while the agreement opens a new revenue stream by allowing Medcolcanna to produce seeds on behalf of DNA Genetics for their customers. The agreement also provides for consulting and advice in growing, post-harvesting, processing, and, in general, advice with respect to cannabis cultivation.
"This alliance is an important milestone to our access to countries under negotiation, such as Germany, Poland, the UK, and Israel, amongst others," says MCCN CEO Felipe de la Vega.
For more information: